New Report: 72 Million Adults in the US Lack Dental Insurance, Nearly Three Times the Number Without Health Insurance
BOSTON--(BUSINESS WIRE)-- A new report from CareQuest Institute for Oral Health ® reveals that 27% of US adults — an estimated 72 million people — do not have dental insurance, nearly three times the number of adults who lack health insurance (9.5%, or 26 million). The findings, from the latest State of Oral Health Equity in America (SOHEA) survey, underscore a persistent and troubling gap in access to dental care.
Lack of dental insurance puts adults at risk for delayed treatment and worsening oral health, which is closely tied to broader health problems, including diabetes, heart disease, and even dementia.
'These findings reinforce the fact that oral health care is too expensive and out of reach for too many families in America,' said Melissa Burroughs, Senior Director of Public Policy at CareQuest Institute. 'Gaps in dental insurance force families to make impossible tradeoffs between things like putting food on the table and getting the care they need — any cuts to the Medicaid program would only make this problem worse. It's time for policy solutions that address our nation's oral health, starting by preserving Medicaid adult dental coverage.'
The report, Out of Pocket: A Snapshot of Adults' Dental and Medical Care Coverage, also finds that:
Adults with lower incomes and education levels are more likely to lack dental insurance. 40% of adults without a high school diploma and 38% of those earning under $30,000 annually are uninsured for dental care.
One-third of adults with Medicare or Medicaid lack dental coverage. Traditional Medicare does not include dental services, and Medicaid adult dental coverage varies widely by state.
More than 80% of adults without health insurance also lack dental insurance.
Nearly one in four adults with dental insurance gained it in the last year, either by changing from a previous insurance plan to a new plan or by enrolling in an insurance plan after being uninsured.
Among adults currently without dental insurance, 12% lost coverage in the past year, disproportionately affecting younger adults and Asian/Pacific Islander, Black, and Hispanic adults.
Despite growing recognition that oral health is essential to overall health, significant policy gaps remain. Medicare does not guarantee dental coverage, Medicaid coverage for adults is optional and inconsistent across states, and marketplace dental plans often lack affordability and accessibility, with no subsidies available.
The SOHEA survey is the largest nationally representative survey focused exclusively on oral health attitudes, behaviors, and experiences among adults. Conducted from March to May 2024 by the National Opinion Research Center (NORC) at the University of Chicago, the study reflects the voices of more than 9,000 adults nationwide.
The full report is available here.
About CareQuest Institute for Oral Health ®
CareQuest Institute for Oral Health ® is a national nonprofit championing a more equitable future where every person can reach their full potential through excellent health. We do this through our work in philanthropy, analytics and data insights, health transformation, policy and advocacy, and education, as well as our leadership in dental benefits and innovation advancements. We collaborate with thought leaders, health care providers, patients, and local, state, and federal stakeholders to accelerate oral health care transformation and create a system designed for everyone. To learn more, visit carequest.org and follow us on Twitter/X, LinkedIn, Facebook, and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Concerns raised over unintentional coverage losses at final Medicaid work requirements hearing
The Sioux Falls One Stop houses offices for several state departments, including Health, Social Services and Revenue. It hosted a hearing for proposed Medicaid expansion work requirements on June 12, 2025. (Makenzie Huber/South Dakota Searchlight) More than a dozen people raised concerns and questions about unintentionally separating patients from their health care and other aspects of South Dakota's proposed Medicaid expansion work requirements during the plan's final public hearing Thursday in Sioux Falls. Dana Bacon, state government affairs director at The Leukemia and Lymphoma Society, told the state Department of Social Services his organization has 'pretty big concerns' due to the technical problems, costs and unintended loss of coverage that people encountered during attempted work requirements in other states. 'That's going to make individuals, families, systems and communities pay a price for the outcomes,' Bacon said. 'We have a good sense of where this waiver is going, but we still see these problems getting in the way of the stated goal of making sure people get the health care they need.' Written comments about South Dakota's Medicaid expansion work requirements proposal may be submitted by June 18 via email to MedicaidSPA@ with the subject line 'SDCareerLink Public Comment,' or mailed to the Division of Medical Services, Department of Social Services, 700 Governors Drive, Pierre, SD 57501-2291. Other people questioned the need to implement work requirements and expressed concern about a potentially disproportionate impact on tribal members, as well as the potential barrier the plan could create to health care for sick, homeless and older people. Medicaid is government-funded health insurance for people with low incomes. South Dakotans voted in 2022 to expand Medicaid to adults with incomes up to 138% of the poverty level, a decision that allowed the state to capitalize on a 90% federal funding match — funding that could be in jeopardy, pending the outcome of congressional action. Last year, voters passed another constitutional amendment to let the state seek approval from the federal government to impose work requirements on expansion enrollees. The state began drafting its proposal immediately following the end of the state legislative session in March, before debates about potential federally imposed work requirements heated up at the congressional level. Those debates are ongoing. The department only heard from one person at its first hearing in May. The state is also accepting written comments through Wednesday, which will be included in the state's application to the Centers for Medicare and Medicaid Services later this summer. South Dakota's plan would require adult Medicaid recipients to work, train, attend school or serve as a caretaker for a child or elderly or disabled person in their home unless they qualify for an exception. Compliance with the state-level work rules would be reviewed on an annual basis, at the time of Medicaid renewal, rather than at the time of application. The state would not require a set number of hours of work or education time. South Dakota would allow exceptions for people who are: Pregnant or up to 12 months postpartum. Disabled, as determined by the Social Security Administration. Diagnosed with cancer or another serious or terminal medical condition by a physician. In an intensive behavioral health treatment program, hospitalized or living in a nursing home. In an area with unemployment 20% or more above the national average and are exempt from Supplemental Nutrition Assistance Program requirements for able-bodied adults without dependents. As of last month, 30,542 South Dakotans were covered by the Medicaid expansion. The state estimates 80% of them already work or qualify for an exception. The proposed state-level work requirement would reduce enrollment by an estimated 5-10% in the first year. That would save the Medicaid program between $48.9 million and $71 million in the first year, the department says. Federal action could make SD's Medicaid work requirements 'an exercise in futility,' official says Department officials explained that expansion enrollees would be sent three notices before being removed from Medicaid rolls. People could reapply later if they don't meet work requirements at their renewal time. Heather Petermann, Medicaid director at the department, said people who are seeking treatment for substance use disorder or other mental health disorders outside of intensive treatment programs could obtain an exemption if their physician or health care provider provided documentation that they can't work because of their condition. Department Secretary Matt Althoff said the state's proposal is meant to be administratively simple and to encourage work among Medicaid recipients rather than track hours. 'We are helping them, we believe, not only by providing a safety net, but a lift up. Isn't it true that personal industry is the antidote to poverty?' Althoff said. 'The more that we can do to discover fulfillment through serving others, the more that we can do to garner an income that we earn, the higher likelihood we will be able to escape the clutches of poverty.' Other suggestions made during public comment during the hearing included: Adding volunteer or community service time as an exemption, to benefit older adults who can't find employment because of their age. Exempting Indian Health Service beneficiaries, since they are eligible for Medicaid coverage at the federal level even if they do not meet other Medicaid requirements, such as income limits. Allowing more flexibility to exempt caregivers of older adults who don't share the same residence. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
an hour ago
- Yahoo
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs. NUMELVI, a once-daily, first-line treatment, will be the only second-generation Janus kinase (JAK) inhibitor indicated for the treatment of pruritus associated with allergic dermatitis including atopic dermatitis and treatment of clinical manifestations of atopic dermatitis in dogs, upon full approval by the European Commission. NUMELVI inhibits the function of JAK1-dependent cytokines involved in itch and inflammation in allergic and atopic dermatitis and is at least 10-fold more selective for JAK1 compared to the other JAK family members (JAK2, JAK3 and TYK2). JAK1 selectivity minimizes interference with cytokines involved in hematopoiesis and immune functions dependent on the other JAKs, resulting in a compelling safety profile with proven efficacy in dogs and puppies. Once approved, it will be the only JAK inhibitor that can be used in dogs as young as six months of age. With a once-daily treatment regimen, NUMELVI is clinically effective after the first dose. Treatment with NUMELVI had no impact on immune response to vaccination. "Merck Animal Health has been committed to bringing innovation to our customers aimed at rapidly controlling and treating a common condition that causes distress for so many pets and pet owners," said Rick DeLuca, executive vice president and president, Merck Animal Health. "With today's positive opinion for NUMELVI, we are one step closer to making this novel, highly selective JAK inhibitor available." Itch is seen in more than 20 percent of dogs in general veterinary practice and is one of the most frequent reasons for veterinary visits. As allergic dermatitis progresses, quality of life in dogs declines and the relationship between a pet and its owner can be weakened due to emotional distress, interruptions in sleep and routines, increased expenses, and time lost to provide treatment and veterinary follow-up to manage an itchy dog. Veterinarians also face challenges in managing dogs with allergic dermatitis, as diagnosis and treatment takes time and requires regular progress checks. "Merck Animal Health continues to deliver cutting-edge innovation and science with first- and best-in-class veterinary medicinal products that address important unmet needs," said Holger Lehmann, DVM, PhD, vice present and global head, research and development for pharmaceuticals, Merck Animal Health. "NUMELVI not only offers a once-daily dosing regimen but also features a distinctive safety profile that permits its use in dogs as young as six months. Additionally, a vaccine response study has shown that NUMELVI does not affect the immune response to core vaccinations." Based on the CVMP's recommendation, the European Commission is expected to issue a decision for marketing authorization in the European Union (EU) during the third quarter of 2025. About Merck Animal Health At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( View source version on Contacts Media:Kim Gorode973-255-8094ahglobalmedia@ Investor:Peter
